SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Retension Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update

FALLS CHURCH, Va., Nov. 18, 2026 (GLOBE NEWSWIRE) -- Retension Pharmaceuticals, Inc. NASDAQ:RTSN (“Retension” or the “Company”), a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases, today reported financial r…

RTSN

Related stories